Last update Aug. 29, 2022

Dupilumab

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps associated with chronic rhinosinusitis. Subcutaneous administration every 2 weeks.

Since the last update we have not found published data on its excretion in breastmilk.

It´s very high molecular weight (> 100,000 Da) makes it very unlikely to pass into breast milk in a significant quantity.

Due to its protein nature, it is inactivated in the gastrointestinal tract without being absorbed (practically nil oral bioavailability) and this hinders or prevents its passage into the infant´s plasma from ingested breast milk, except for premature infants and during the immediate neonatal period when there might be a greater intestinal permeability.

No problems have been seen in an infant whose mother was treated with dupilumab. (Kage 2021 and 2020)

 

Alternatives

We do not have alternatives for Dupilumab.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dupilumab in other languages or writings:

  • دوبيلوماب (Arabic)
  • Дупилумаб (Cyrillic)
  • 度匹芦人单抗 (Chinese)
  • Immunoglobulin, anti-(human interleukin 4 receptor alpha) (human regn668 heavy chain), disulfide with human regn668 kappa-chain, dimer (Chemical name)
  • C6512H10066N1730O2052S46 (Molecular formula)
  • D11AH05 (ATC Code/s)

Groups

Dupilumab belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Dupilumab in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 146.897 daltons
VD 0.07 l/Kg
Tmax 72 - 168 hours
> 240 hours

References

  1. Stratigakis A, Paty D, Zou P, Zhao Z, Li Y, Zhang T. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207 Full text (link to original source) Full text (in our servers)
  2. Kage P, Simon JC, Treudler R. Case of atopic eczema treated with dupilumab throughout conception, pregnancy, and lactation. J Dermatol. 2021 Oct;48(10):E484-E485. Abstract
  3. Treudler R, Kage P, Simon JC. A case of atopic eczema treated safely with dupilumab during pregnancy and lactation. Allergy. 2020;75 Suppl. 109:432. Abstract 0071. Abstract Full text (link to original source) Full text (in our servers)
  4. EMA. Dupilumab. Ficha técnica. 2017 Full text (in our servers)
  5. Sanofi. Dupilumab. Drug Summary. 2017 Full text (in our servers)

Total visits

1,996

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM